Please login to the form below

Not currently logged in
Email:
Password:

insulin degludec

This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation

Latest news

More from news
Approximately 13 fully matching, plus 59 partially matching documents found.

Latest Intelligence

  • Interview: Peter Meeus, Novo Nordisk Interview: Peter Meeus, Novo Nordisk

    Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics